NCT06977308View on ClinicalTrials.gov

A Multimodal Imaging Study of Dopamine in Early Psychosis

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2029

Study Completion Date

October 1, 2030

Conditions
Clinical High Risk for Psychosis (CHR)
Interventions
DRUG

Methylphenidate (MPH)

Each participate will receive one oral dose of 60mg methylphenidate.

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

collaborator

Columbia University Irving Medical Centre

UNKNOWN

collaborator

Research Foundation for Mental Hygiene, Inc. / Columbia University

UNKNOWN

lead

New York State Psychiatric Institute

OTHER